174 related articles for article (PubMed ID: 32409713)
1. Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes.
Engqvist H; Parris TZ; Biermann J; Rönnerman EW; Larsson P; Sundfeldt K; Kovács A; Karlsson P; Helou K
Sci Rep; 2020 May; 10(1):7946. PubMed ID: 32409713
[TBL] [Abstract][Full Text] [Related]
2. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
[TBL] [Abstract][Full Text] [Related]
3. The Evolution of Ovarian Carcinoma Subclassification.
Köbel M; Kang EY
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053578
[TBL] [Abstract][Full Text] [Related]
4. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
5. Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry.
Engqvist H; Parris TZ; Kovács A; Rönnerman EW; Sundfeldt K; Karlsson P; Helou K
Front Oncol; 2020; 10():162. PubMed ID: 32133296
[TBL] [Abstract][Full Text] [Related]
6. Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma.
Werner Rönnerman E; Pettersson D; Nemes S; Dahm-Kähler P; Kovács A; Karlsson P; Parris TZ; Helou K
Front Oncol; 2022; 12():1112152. PubMed ID: 36818673
[TBL] [Abstract][Full Text] [Related]
7. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.
Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001
[No Abstract] [Full Text] [Related]
10. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Köbel M; Kang EY; Weir A; Rambau PF; Lee CH; Nelson GS; Ghatage P; Meagher NS; Riggan MJ; Alsop J; Anglesio MS; Beckmann MW; Bisinotto C; Boisen M; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; Deen S; El-Bahrawy MA; Elishaev E; Erber R; Fereday S; ; Fischer A; Gayther SA; Barquin-Garcia A; Gentry-Maharaj A; Gilks CB; Gronwald H; Grube M; Harnett PR; Harris HR; Hartkopf AD; Hartmann A; Hein A; Hendley J; Hernandez BY; Huang Y; Jakubowska A; Jimenez-Linan M; Jones ME; Kennedy CJ; Kluz T; Koziak JM; Lesnock J; Lester J; Lubiński J; Longacre TA; Lycke M; Mateoiu C; McCauley BM; McGuire V; Ney B; Olawaiye A; Orsulic S; Osorio A; Paz-Ares L; Ramón Y Cajal T; Rothstein JH; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Steed H; Storr SJ; Talhouk A; Traficante N; Wang C; Whittemore AS; Widschwendter M; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Campbell I; Cook LS; DeFazio A; Doherty JA; Fasching PA; Fortner RT; García MJ; Goodman MT; Goode EL; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Kommoss S; Le ND; Martin SG; Menon U; Modugno F; Pharoah PD; Schildkraut JM; Sieh W; Staebler A; Sundfeldt K; Swerdlow AJ; Ramus SJ; Brenton JD
J Pathol Clin Res; 2023 May; 9(3):208-222. PubMed ID: 36948887
[TBL] [Abstract][Full Text] [Related]
11. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
Okoye E; Euscher ED; Malpica A
Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
[TBL] [Abstract][Full Text] [Related]
12. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
Sugino K; Tamura R; Nakaoka H; Yachida N; Yamaguchi M; Mori Y; Yamawaki K; Suda K; Ishiguro T; Adachi S; Isobe M; Yamaguchi M; Kashima K; Motoyama T; Inoue I; Yoshihara K; Enomoto T
Sci Rep; 2019 Nov; 9(1):17808. PubMed ID: 31780705
[TBL] [Abstract][Full Text] [Related]
13. Histotype classification of ovarian carcinoma: A comparison of approaches.
Peres LC; Cushing-Haugen KL; Anglesio M; Wicklund K; Bentley R; Berchuck A; Kelemen LE; Nazeran TM; Gilks CB; Harris HR; Huntsman DG; Schildkraut JM; Rossing MA; Köbel M; Doherty JA
Gynecol Oncol; 2018 Oct; 151(1):53-60. PubMed ID: 30121132
[TBL] [Abstract][Full Text] [Related]
14. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
Le Page C; Rahimi K; Köbel M; Tonin PN; Meunier L; Portelance L; Bernard M; Nelson BH; Bernardini MQ; Bartlett JMS; Bachvarov D; Gotlieb WH; Gilks B; McAlpine JN; Nachtigal MW; Piché A; Watson PH; Vanderhyden B; Huntsman DG; Provencher DM; Mes-Masson AM
BMC Cancer; 2018 Mar; 18(1):347. PubMed ID: 29587661
[TBL] [Abstract][Full Text] [Related]
16. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
18. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
19. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
